Return to Statistics Toolbox

Dot Plot analysis for Study ST001237

Select one or more experimental factors for control and test groups. The members of each group should be DIFFERENT.
Control(s)Experimental factorTest(s)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (39)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (14)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (45)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (13)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (41)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (6)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (47)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (11)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (5)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (1)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (12)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (2)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (51)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (19)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (57)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (19)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (92)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (24)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (95)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (29)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (39)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (18)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (47)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (15)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (9)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (3)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (21)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (3)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (6)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (2)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (13)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (3)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (3)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (5)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (1)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (10)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (1)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (10)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (5)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (16)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (3)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (20)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (7)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (3)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (2)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (8)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (2)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (44)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (12)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (41)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (10)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (12)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (2)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (42)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (15)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (74)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (24)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (38)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (10)
x-axis labels ?: Show a single class:
P-value cutoff:    Fold-change cutoff:    Sample normalization:
Use:   Maximum # of individual metabolites to display:
Group by:   Maximum # of (most significant) metabolites per class to use in group calculation:
Analysis:Combine data for all analyses?:     

  logo